BioHiTech GlobalPlacement Agent Agreement • September 6th, 2019 • Biohitech Global, Inc. • Services-educational services • New York
Contract Type FiledSeptember 6th, 2019 Company Industry Jurisdiction
Lishan Aklog, M.D. Chairman & Chief Executive Officer PAVmed Inc. One Grand Central Place, Suite 4600 New York, NY 10165 Dear Dr. Aklog:Placement Agent Agreement • April 12th, 2019 • PAVmed Inc. • Surgical & medical instruments & apparatus • New York
Contract Type FiledApril 12th, 2019 Company Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and PAVmed Inc. (the “Company”), that Maxim shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered shares (the “Shares” or the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement shall be collectively referred to herein as the “Transacti
Mr. Marc Voigt Chief Executive Officer Prima BioMed Ltd Level 12, 95 Pitt Street, Sydney, 2000 New South Wales, Australia Dear Marc:Placement Agent Agreement • June 29th, 2017 • Prima BioMed LTD • Pharmaceutical preparations • New York
Contract Type FiledJune 29th, 2017 Company Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Prima BioMed Ltd (the “Company”), that Maxim shall serve as the lead placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered American Depositary Shares (the “ADSs”), each evidencing one hundred Ordinary Shares of the Company (the “Ordinary Shares”) and Warrants to purchase ADSs. The terms of the Placement and the ADSs and warrants shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any ADSs or Warrants or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement shall be col
Mr. Eutillio Buccilli Chief Executive Officer Genetic Technologies LimitedPlacement Agent Agreement • December 2nd, 2016 • Genetic Technologies LTD • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 2nd, 2016 Company Industry Jurisdiction
SUBJECT TO COMMITMENTS COMMITTEE APPROVALPlacement Agent Agreement • June 30th, 2016 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 30th, 2016 Company Industry Jurisdiction
Mr. W. John Short Chief Executive Officer RiceBran TechnologiesPlacement Agent Agreement • February 17th, 2016 • RiceBran Technologies • Grain mill products • New York
Contract Type FiledFebruary 17th, 2016 Company Industry Jurisdiction
Mr. Zami Aberman, Chairman of Board of Directors & Chief Executive OfficerPlacement Agent Agreement • June 25th, 2015 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 25th, 2015 Company Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Pluristem Therapeutics Inc. (the “Company”), that Maxim shall serve as the lead placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) registered shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) to purchase shares of Common Stock (the shares of Common Stock underlying the Warrants, “Warrant Shares” and, together with the Shares and the Warrants, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or com
Mr. Eutillio Buccilli Chief Executive Officer Genetic Technologies LimitedPlacement Agent Agreement • March 6th, 2015 • Genetic Technologies LTD • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 6th, 2015 Company Industry Jurisdiction
Mr. Dwight Babcock Chairman & Chief Executive Officer IsoRay, Inc.Placement Agent Agreement • March 21st, 2014 • IsoRay, Inc. • Surgical & medical instruments & apparatus • New York
Contract Type FiledMarch 21st, 2014 Company Industry Jurisdiction
Mr. Gil Van Bokkelen Chief Executive Officer Athersys, Inc.Placement Agent Agreement • January 13th, 2014 • Athersys, Inc / New • Pharmaceutical preparations • New York
Contract Type FiledJanuary 13th, 2014 Company Industry Jurisdiction
Mr. Gil Van Bokkelen Chief Executive Officer Athersys, Inc.Placement Agent Agreement • November 29th, 2013 • Athersys, Inc / New • Pharmaceutical preparations • New York
Contract Type FiledNovember 29th, 2013 Company Industry Jurisdiction